An Observational Study of Efficacy and Safety of Modern Insulin in Diabetes Patients Switched From Anti-diabetic Treatment

• Status: Completed
• Trial end date: 2009-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is conducted in Asia. The aim of this observational study is to evaluate the safety and efficacy of modern insulins after switch from any other anti-diabetic treatment under normal clinical conditions in the Gulf countries.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Biphasic Insulins; Insulin; Insulin Aspart; Insulin aspart, insulin aspart protamine drug combination 30:70; Insulin degludec, insulin aspart drug combination; Insulin Detemir; Insulin, Globin Zinc; Insulin, Isophane; Insulin, Long-Acting

Criteria

Inclusion Criteria:

• Type 1 or type 2 diabetes

• Treatment with any diabetes treatment other than NovoMix® 30, Levemir® and/or NovoRapid®

• Selection will be at the discretion of the individual physician

Exclusion Criteria:

• Current treatment with Levemir®, NovoMix® 30 and/or NovoRapid®

• Previous enrolled in this study

• Hypersensitivity to Levemir®, NovoMix® 30 and/or NovoRapid® or to any of the excipients

• Women who are pregnant, breast feeding or have the intention of becoming pregnant within next 6 months